HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Abstract
This study prospectively analyzed the efficacy of very prolonged courses of pegylated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase in pediatric acute lymphoblastic leukemia (ALL) patients. Patients received 15 PEGasparaginase infusions (2500 IU/m(2) every 2 weeks) in intensification after receiving native E coli asparaginase in induction. In case of allergy to or silent inactivation of PEGasparaginase, Erwinia asparaginase (20 000 IU/m(2) 2-3 times weekly) was given. Eighty-nine patients were enrolled in the PEGasparaginase study. Twenty (22%) of the PEGasparaginase-treated patients developed an allergy; 7 (8%) showed silent inactivation. The PEGasparaginase level was 0 in all allergic patients (grade 1-4). Patients without hypersensitivity to PEGasparaginase had serum mean trough levels of 899 U/L. Fifty-nine patients were included in the Erwinia asparaginase study; 2 (3%) developed an allergy and none silent inactivation. Ninety-six percent had at least 1 trough level ≥100 U/L. The serum asparagine level was not always completely depleted with Erwinia asparaginase in contrast to PEGasparaginase. The presence of asparaginase antibodies was related to allergies and silent inactivation, but with low specificity (64%). Use of native E coli asparaginase in induction leads to high hypersensitivity rates to PEGasparaginase in intensification. Therefore, PEGasparaginase should be used upfront in induction, and we suggest that the dose could be lowered. Switching to Erwinia asparaginase leads to effective asparaginase levels in most patients. Therapeutic drug monitoring has been added to our ALL-11 protocol to individualize asparaginase therapy.
AuthorsWing H Tong, Rob Pieters, Gertjan J L Kaspers, D Maroeska W M te Loo, Marc B Bierings, Cor van den Bos, Wouter J W Kollen, Wim C J Hop, Claudia Lanvers-Kaminsky, Mary V Relling, Wim J E Tissing, Inge M van der Sluis
JournalBlood (Blood) Vol. 123 Issue 13 Pg. 2026-33 (Mar 27 2014) ISSN: 1528-0020 [Electronic] United States
PMID24449211 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies
  • Antineoplastic Agents
  • Escherichia coli Proteins
  • pegaspargase
  • Polyethylene Glycols
  • Asparaginase
Topics
  • Adolescent
  • Antibodies (blood)
  • Antineoplastic Agents (therapeutic use)
  • Asparaginase (administration & dosage, immunology)
  • Child
  • Child, Preschool
  • Drug Monitoring
  • Erwinia (enzymology)
  • Escherichia coli Proteins (therapeutic use)
  • Female
  • Humans
  • Infant
  • Male
  • Polyethylene Glycols (administration & dosage)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: